argenx to Present Phase 3 ALKIVIA Results at ACR Convergence 2026
The company says Phase 3 ALKIVIA results in autoimmune myositis will be presented as a late-breaking oral presentation at ACR Convergence 2026.
Story updates
12:04:38 PM UTC
SquawkNews
argenx will present late-breaking Phase 3 ALKIVIA results for VYVGART Hytrulo in autoimmune myositis (IMNM and DM) at ACR Convergence 2026 on Nov. 11.Material DetailsContext by AI AnalystThis is a late-stage readout in an expansion indication for efgartigimod, extending beyond gMG/CIDP into myositi…